Dr. Bronner’s to Provide Employees with Ketamine-Assisted Therapy

March 8, 2022 15:19:38

In a recent press release, Dr. Bronner’s revealed that it had broadened its mental healthcare coverage as the first step in its strategy to provide access to psychedelic-assisted therapy to its employees as a means to promote mental health.

This plan, which includes the use of ketamine in combination with therapy, is to be administered by Enthea, a not-for-profit healthcare organization that is responsible for benefit plan administration, provider network management and medical policy development. The organization also establishes quality-of-care standards for provided treatments, including the management of a specialty provider network.

Dr. Bronner’s is collaborating with Enthea because both entities believe that psychedelic-assisted therapies should be integrated into standard mental healthcare because they can be used to effectively treat various health issues. Both organizations also believe that these substances possess the potential to heal people and save lives.

Dr. Bronner’s has supported political campaigns, advocacy organizations and public education efforts in different parts of the country that are focused on advancing the acceptance and availability of psychedelic-assisted therapy for the treatment of post-traumatic stress disorder, anxiety and depression among other conditions.

In the press release, Dr. Bronner’s CEO Michael Bronner stated that the well-being and health of the company’s employees was the main driver of the initiative, noting that providing coverage for ketamine-assisted therapy would allow employees to have the best options for mental healthcare as well as the best quality of life. Bronner added that the current mental health crisis, which has been exacerbated by the coronavirus pandemic, was another driving force behind the decision. These employee benefits came into effect on Jan. 1, 2022. The offering comprises of ketamine sessions combined with specialized counselling services to improve mental health issues.

Ketamine is an anesthetic that has dissociative effects when administered in subanesthetic doses. It is the only FDA-approved prescription drug with efficacy data for the treatment of mental health conditions.

Enthea’s chief medical officer Dan Rome stated that the efficacy of ketamine-assisted therapy had been seen in decades of accumulated clinical experience as well as numerous studies. He noted that the society was in need of more effective mental disorder treatments, which would reduce the economic toll on the healthcare system while also decreasing human suffering.

Figures show that in the United States, substance use disorders and mental health conditions affect more than 70 million individuals and about 970 million individuals respectively, with more than one-third of patients reporting no improvements after receiving standard treatments for depression.

The decision by Dr. Bronner’s to make ketamine treatments available to its staff who need it is a big endorsement to sector actors such as Delic Holdings Corp. (CSE: DELC) (OTC: DELCF), which have invested heavily in bringing ketamine infusion centers as close to the people who need those treatments as possible.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.